Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

10 results
Display

Clinical Studies of Risperidone in Korea

Kwon JS, Ha TH

  • KMID: 1856375
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):128-139.
There have been 91 papers on risperidone in Korea, which were composed of 21 reviews, 9 preclinical studies, 18 case reports, and 43 clinical trials, since this new antipsychotic was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Efficacy and Safety of Risperidone in Patients with Schizophrenia

Kim CY, Park CH

  • KMID: 1856370
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):58-69.
Most informations on the efficacy and safety of new antipsychotic durgs are based on short-term clinical trials. Short-term studies are usually conducted as well-controlled, randomized, comparative studies. However, they do...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Optimal Dosing and Recommended Dose-Schedule with Risperidone

Kim CH, Lee HS

  • KMID: 1856369
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):46-57.
Although the establishment of appropriate dosage ranges and dose-up strategies for antipsychotic drugs has important ramifications for both short-term treatment and long-term therapeutic outcomes, difficulties in dosing persist. As a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pre-Clinical Study of Risperidone

Chung IW

  • KMID: 1856366
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):5-15.
Pre-clinical study has been carried out to explore the pharmacology, mechanism of actions, and toxicology of candidate materials for the new therapeutic drugs, and the additional biological mechanisms of drugs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risperidone for Psychogeriatric Patients

Kim SH, Lee BH

  • KMID: 1856373
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):101-111.
Elderly patients with dementia, delirium, schizophrenia and other psychotic symptoms are appropriate candidates for antipsychotic treatment. Risperidone is one of the newer atypical antipsychotic agents, which block serotonin and dopamine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Clinical Use of Risperidone in Child & Adolescent Psychiatry

Kim BN

  • KMID: 1856374
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):112-127.
The use of the antipsychotic drug, one of the most frequently prescribed drugs in child & adolescent psychiatry, has been limited because of the diverse serious side effects and questionable...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effectiveness and Safety of Risperidone on Bipolar Disorders

Bahk WM, Lee KU

  • KMID: 1856371
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):70-85.
Bipolar disorders affect about 1-2.5% of the population. They are leading causes of disability and associated with significant health care costs. Antipsychotic medicaitons have a long history of use in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Trials of Risperidone in the Patients with Schizophrenia: Comparison with Other Antipsychotics

Kim YH

  • KMID: 1856368
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):32-45.
Several double-blind comparative studies and two combined analysis of double-blind studies comparing the safety, tolerability and clinical efficacy of risperidone with those of haloperidol and other atypical antipsychotics were reviewed....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risperidone Beyond Psychoses

Yoon DJ, Bahn GH

  • KMID: 1856372
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):86-100.
The authors have compiled the available references on the use of risperidone in 'non-psychotic conditions', not including schizophrenia and bipolar disorders. In addition, information was gathered on the mechanism of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risperidone: the Korean Experience in the Treatment of Patients with Schizophrenic Disorder

Yoon JS, Bae KL

  • KMID: 1856367
  • Korean J Psychopharmacol.
  • 2003 Feb;14(Suppl):16-31.
Since the introduction in 1996 of the novel antipsychotic risperidone in Korea, clinical experiences with this agent for the treatment of schizophrenia have been accumulated. This article attempts to review...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr